Donor and Recipient Age-Mismatches: The Potential of Transferring Senescence

Iske, Jasper; Matsunaga, Tomohisa; Zhou, Hao; Tullius, Stefan G.

doi:10.3389/fimmu.2021.671479

Cited by 12 publications

(11 citation statements)

References 86 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emerging research shows that lung transplant-related injury may lead to accelerated aging in the graft and that senescence can be transmitted from transplanted cells. 13,14 Finally, it is possible that some latent driver of both frailty and CLAD could explain our findings. If it turns out that 1 of the latter 2 broad potential relationships is true, it would suggest that frailty may be an early "biomarker" of CLAD risk rather than lying on the causal pathway.…”

Section: Discussionmentioning

confidence: 81%

The Association Between Frailty and Chronic Lung Allograft Dysfunction After Lung Transplantation

et al. 2023

View full text Add to dashboard Cite

Background. After lung transplantation, both frailty and chronic lung allograft dysfunction (CLAD) commonly develop, and when they do, are associated with poorer outcomes. Given their potential shared mechanisms, we sought to explore the temporal relationship between frailty and CLAD onset. Methods. In a single center, we prospectively measured frailty by the short physical performance battery (SPPB) repeatedly after transplant. Because of the nature of the relationship between frailty and CLAD is unknown, we tested the association between frailty, modeled as a time-dependent predictor, and CLAD development as well as CLAD development, modeled as a time-dependent predictor, and frailty development. To do so, we used Cox proportional cause-specific hazards and conditional logistic regression models adjusted for age, sex, race, diagnosis, cytomegalovirus serostatus, posttransplant body mass index, and acute cellular rejection episodes as time-dependent covariates. We tested SPPB frailty as a binary (≤9 points) and continuous predictor (12-point scale); as an outcome, we defined frailty as SPPB ≤9. Results. The 231 participants were a mean age of 55.7 y (SD 12.1). After adjusting for covariates, the development of frailty within 3 y after lung transplant was associated with cause-specific CLAD risk (adjusted cause-specific hazard ratio: 1.76; 95% confidence interval [CI], 1.05-2.92 when defining frailty as SPPB ≤9 and adjusted cause-specific hazard ratio: 1.10, 95% CI, 1.03-1.18 per 1-point worsening in SPPB). CLAD onset did not appear to be a risk factor for subsequent frailty (odds ratio, 4.0; 95% CI, 0.4-197.0). Conclusions. Studying the mechanisms underlying frailty and CLAD could provide new insights into the pathobiology of both and potential targets for intervention.

show abstract

Section: Discussionmentioning

confidence: 81%

The Association Between Frailty and Chronic Lung Allograft Dysfunction After Lung Transplantation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…After aging organ transplantation, the expression of SASP in recipients will be significantly increased to induce the aging of young cell cells, and even the aging cell population. Accumulation of mtDNA also greatly reduces the survival rate of transplanted organs ( 79 , 80 ). In the experiment of Jasper Iske et al.…”

Section: Mechanisms Of Ageingmentioning

confidence: 99%

The impact of ageing mechanisms on musculoskeletal system diseases in the elderly

Cai,

Han,

Cheng

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Ageing is an inevitable process that affects various tissues and organs of the human body, leading to a series of physiological and pathological changes. Mechanisms such as telomere depletion, stem cell depletion, macrophage dysfunction, and cellular senescence gradually manifest in the body, significantly increasing the incidence of diseases in elderly individuals. These mechanisms interact with each other, profoundly impacting the quality of life of older adults. As the ageing population continues to grow, the burden on the public health system is expected to intensify. Globally, the prevalence of musculoskeletal system diseases in elderly individuals is increasing, resulting in reduced limb mobility and prolonged suffering. This review aims to elucidate the mechanisms of ageing and their interplay while exploring their impact on diseases such as osteoarthritis, osteoporosis, and sarcopenia. By delving into the mechanisms of ageing, further research can be conducted to prevent and mitigate its effects, with the ultimate goal of alleviating the suffering of elderly patients in the future.

show abstract

“…This property is manifested at the organ level; for instance, in adult recipients, kidneys from young donors show an advantage in engraftment and a lower risk of rejection compared to kidneys from older donors [ 84 ]. Moreover, it has been shown that the organs of elderly donors had a negative effect on the recipients, accelerating the aging of their bodies [ 85 ].…”

Section: Cell and Genetically Modified Cell-based Therapymentioning

confidence: 99%

Eternal Youth: A Comprehensive Exploration of Gene, Cellular, and Pharmacological Anti-Aging Strategies

Kitaeva,

Solovyeva,

Blatt

et al. 2024

IJMS

View full text Add to dashboard Cite

The improvement of human living conditions has led to an increase in average life expectancy, creating a new social and medical problem—aging, which diminishes the overall quality of human life. The aging process of the body begins with the activation of effector signaling pathways of aging in cells, resulting in the loss of their normal functions and deleterious effects on the microenvironment. This, in turn, leads to chronic inflammation and similar transformations in neighboring cells. The cumulative retention of these senescent cells over a prolonged period results in the deterioration of tissues and organs, ultimately leading to a reduced quality of life and an elevated risk of mortality. Among the most promising methods for addressing aging and age-related illnesses are pharmacological, genetic, and cellular therapies. Elevating the activity of aging-suppressing genes, employing specific groups of native and genetically modified cells, and utilizing senolytic medications may offer the potential to delay aging and age-related ailments over the long term. This review explores strategies and advancements in the field of anti-aging therapies currently under investigation, with a particular emphasis on gene therapy involving adeno-associated vectors and cell-based therapeutic approaches.

show abstract

Donor and Recipient Age-Mismatches: The Potential of Transferring Senescence

Cited by 12 publications

References 86 publications

The Association Between Frailty and Chronic Lung Allograft Dysfunction After Lung Transplantation

The Association Between Frailty and Chronic Lung Allograft Dysfunction After Lung Transplantation

The impact of ageing mechanisms on musculoskeletal system diseases in the elderly

Eternal Youth: A Comprehensive Exploration of Gene, Cellular, and Pharmacological Anti-Aging Strategies

Contact Info

Product

Resources

About